Journey Medical Corporation (DERM)

Nasdaq: DERM · Pharmaceutical Preparations · Scottsdale, AZ · filing with the SEC since 2021

Full chart Alerts Compare

Grade4.7

◀ Past 5.3● Present 4.8▶ Future 3.8

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$61.2M+11.1%

Net income-$11.4M+22.1%

Earnings per share$-0.47+34.7%

Operating cash flow-$12.4M-36.3%

Cash$24.1M+18.6%

Debt$25.3M+1.6%

Shareholders’ equity$31.9M+58.7%

Shares, diluted24.5M+19.9%

Return on equity-35.9%

The recordfrom its filings

Filings in 202633

Newest filingNov 12 · 10-Q

Annual reportMar 26, 2026

Quarterly reportNov 12, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted6

Filer category<br>Emerging growth company

Trailing twelve months to Sep 2026Revenue $68.8MNet income -$5.1MCash from operations -$8.5Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 12, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Oct 9, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Aug 12, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Aug 12, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Jul 31, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Jul 15, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Jul 2, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Jul 2, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Jul 2, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Journey Medical Corporation is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Scottsdale, AZ. Qbrexza was 41% of fiscal 2025 revenue.

Newest on the record

Quarterly report on Nov 12. Before it, current report on Nov 12.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About DERM

Journey Medical Corporation is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Scottsdale, AZ. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $61 million and a loss of $11 million (its filed statements).

IndustryPharmaceutical Preparations

HeadquartersScottsdale, AZ

Business modelProduct business

ExchangeNasdaq

Filing since2021

Fiscal year endsDec 31

SEC number (CIK)1867066

Peers on fileETON, AYTU, CELU, KPTI

Who runs it

Financial performance

In fiscal 2025 Journey Medical’s revenue was $61.24 million, up 11.1% from $55.13 million the year before. It made a net loss of $11.43 million.

Annual report, filed Mar 26, 2026.

Financial statements

The grade

Journey Medical grades 4.7 of 10 against its own industry, the 497 companies in Pharmaceutical Preparations. Seven of the nine metrics are read as filed and two are SI estimates, each with its reasoning.

◀ Past5.3

● Present4.8

▶ Future3.8

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton DERM · research, not advice